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Photoradiation Therapy for Cutaneous and Subcutaneous Malignancies 
THOMAS J. DOUGHERTY, PH.D. 
Division of Radiation Biology, Roswell Par/l Memorial In.stitute, Buffalo, New Yorh, U.S.A. 
Photoradiation therapy (PRT) using hematoporphyrin 
derivative (Hpd) as the photosensitizing agent is being 
developed for local treatment of a wide variety of malig-
nant lesions including those involving the skin. The larg-
est group of patients in this category are those with 
metastatic breast carcinoma in which 34/35 showed re-
sponse to PRT. Other patients showing response to PRT 
are those with basal cell carcinoma, malignant mela-
noma, and squamou s cell carcinoma. 
Photoradiation t h era py (PRT) is a new technique being 
investigated for treatment of a variety of solid, malignant tu-
mors [1-3). It is based upon t he t umor localizing ability [4- 8] 
and effic ient photod ynamic action [9] of hematoporphyrin de-
rivative (Hpd) resulting in a relatively specific photosensitiza-
tion of m a ligna n t t issue upon exposure to activating vis ible ligh t 
in t h e red regio n of the spectrum. It is fortu itous that t h e 
properties of tumor localization, photodynamic actio n, and ab-
sorption in th e red, combine in t his single materia l. Absorption 
in t h e red (near 630 nm) is a n essential property s ince wa ve-
le ngth s in the red port ion of the visible spectrum are attenuated 
least in t issu e, dropping to approximately 10% in a distance of 
2 cm in a n experimental t umor [I). The cytotoxic agent appears 
to be singret oxygen formed by e ne rgy transfer from t he por-
p hyrin to endogenous oxygen (9). Oxidation and crosslinking of 
membrane components followed by cell lysis is t h e likely mode 
of cell death [10,11). 
A further property of Hpd, useful in tumor localizatio n , is its 
red fluorescence allowing for its easy identification in situ. This 
property, knowt:J for many years [4-7], is currently being u t ilized 
for localization of radiologically occul t lung t umors in high~risk 
patients [7,12). 
This paper presents t h e results of PRT on patients with a 
variety of cutaneous a nd su bcutaneous malignant tumors. 
MATERIALS AND METHODS 
Hematoporphyrin derivative (Hpd) was prepared from hematopor-
phyrin dihydrochloride (Roussel Corp., Paris, France) by acetylation 
and hydrolysis a(;(;ording t.o publ ished procedures [1 ,2]. 
Light Sources 
Light in the red region of the spectrum was derived hom a xenon arc 
la mb (Schoeffel Instrument Corp. , Westwood, NJ) wi th a 6- in. water 
filter, 1.R. refl ecting mirror (Baird Atomic 34-0 1-2), 2 1.R. absorbing 
filt.ers (Corning CS I-75) and a red cut-off filler (Corning CS2-61). T his 
system, most often used with a 4.2 kw lamp, produced a circle of light 
approximately 7 cm in diamet!2 r of 100-150 mw /cm' between 600-700 
nm. Approximately 25% of this spectral range is absorbed by Hpd 
(max imum near 630 nm in t issue). 
For many applications, a dye- laser system was used which produced 
'up to 2.5 w of power at 635±5 nm. A 15-w argon laser (Model 171, 
Spectra-Physics Corp., Mounta in View, CAl was used to pump a dye 
l ~se r (Spectra-Physics Model 375) using Rhodamine B dye. The output 
beam from the dye laser was coupled in to a single 200 IlM quartz fibeJ' 
optic (Quartz S ilice, Paris, France) by means of a modified fiber holder 
(Oriel 'O ptica l Corp ., Stamford , CT) . Coupling efficiencies of near 80% 
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could be achieved over any desirable length of fiber (10 to 40 ft, usually) . 
In some cases, 3 fibers were coupled to the laser beam by pass ing the 
lase r beam through a 70/30 beam splitter (Burleigh Corp., Rochester, 
NY) and then a 50/50 beam splitter, thus producing 3 beams of 
approx imately 30%, 35%, and 35% of the net output power. Overall 
losses in the system were 30- 40%. 
A 3rd light SOUl'ce consisted of a 'bank of 14 flu orescent lamps 
specia lly designed and buil t by GTE Sylvania Corporation which 
produced approximately 4 mw/cm" of power at 590-650 nm and 10 
. mw/cm" in the infrared: 
Patient Selection. 
All patients had biopsy-proven malignancy at least part of which was 
cutaneous or subcutaneous. In many cases, these were metastatic 
lesions which were refractory to conventional therapy. Fully informed 
consent was obtained in al l cases. 
Procedure 
Patients received 2.5 to 5.0 mg/kg body weight Hpd, in t ravenously, 
3 days prior to onset of light therapy. They were cautioned, repeatedly, 
to avoid bright light, indoors and outdoors (especially sunlight), for the 
next 30 days and to expose themselves cautiously. Patients who ignored 
such instructions experienced mild-to-severe sunburn reactions of ex-
posed parts. Generally, the 1st day of light t reatment was limi ted to 
several test areas (2.5 cm") remote from the lesions. For the xenon 
lamp, test doses of 35, 70, and 140 Joules/cm" were used (i.e. 5, 10, 20 
min at U S mw/cm"). When the laser was used, the test doses were 18, 
36 and 72 Joules/em·' delivered over the same time periods. (The laser 
system is more efficient than the xenon la mp since a greater portion of 
its outpu t occurs in the range of Hpd absorption.) In the case of the 
flu orescent lamps, test doses were 50 or 100 Joules/em·' (60 or 120 min). 
Beginning on the 4th day after injection, individual lesions or ar eas 
containing mul t iple lesions were treated with the therapeutic light at 
a dose unlikely to produce skin necrosis, judged from the test area 
resu lts. The light dose was modified on subsequent days, if necessary. 
Wi th some large lesions (>3 em) , the light fiber (sterilized in Cidex) 
was inserted dil·ectly into the lesion through an IS-gauge needle. 
Multiple placements (1-2 em apart) or multiple fibers were used. Ligh t 
doses ranged from 240 to 720 J oules for each placement. 
RESULTS 
The patients described in this report h ave been selected from 
a la rger numbe r of patien ts treated by PRT over the past 4 yr 
[1-3). They a re selected as representative examples of the 
effi cacy of PRT for several types of cu taneous and subcutaneous 
m a lignant t umors. It should be noted, however, that PRT is 
currently be ing evaluated also for treatment of tu mors of the 
b ladder [3], eye [3), a nd lung [3,13). 
Basal Cell Carcinoma 
Basal cell carcinoma lesions can b e effectively treated by 
PRT as s hown by our group [1], K ennedy [3] , and Forbes (3). 
Whil e o nly 5 s uc h lesions h ave been treated to date by t his 
m ethod , in all cases, complete r esponse has been achieved with 
li ttle discomfort to the pa tient. Several of these lesions h ad 
recurred or pe rs isted fo llowing various conventional treatments. 
Case I: Three basal cell lesions (1.0-1.5 cm maximum diam-
eter) on t h e nose a nd face of a 72-yr-old man progressed 
fo llowing surge ry, radiation t herapy and 5-fluorouracii . H e re-
ceived 5.0 mg/ kg Hpd and 4 days later received 120 J ouies/cm2 
of ligh t (20 mi n at 100 mw/cm i ) from t he xe non la mp directed 
tow a rd t h e largest lesion wit h a 0.5 c m margin. A similar light 
dose was g ive n to t his a rea t h e next day. The other lesions were 
not treated. A small eschar form ed over t he treated aTea wi thin 
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2 days which slowly lifted over 4 to 6 weeks, at which time no 
les ion was grossly evident. At follow-up , 7 mo after treatment, 
no tumor was evident in the treated area bu t untreated lesions 
remained, This was the longest follow-up on this patient. Other 
patients t reated with 2,5 mg/ kg Hpd a nd similar light doses 
have been followed over 1 yr to date with complete control of 
tu mor [3]. (J Kennedy, private communication) , 
Kaposi 's Sarcoma 
There have been 3 patients with this disease treated by PRT, 
one each by our group, Kennedy [3, and private communica-
tion] a nd Forbes [3]. In each case, treatment has led to complete 
control of treated lesions although follow-up on 1 pat ient is less 
t han 2 mo at present. The other 2 pat ients have been followed 
over 1 yr. 
Case II: A 70-year-old male had multiple Kaposi's sarcoma 
lesions (0,5 to 2cm) spread over his al'ms and lower limbs, Some 
had been controlled by rad iation therapy, others recurred fol-
lowing radiation, H e received 2.5 mg/ kg Hpd and 3 days later 
received 120 Joules/cm2 to several lesions. The field was con-
firmed to a margin of 2- 3 mm around the lesions, Within 1 
week of treatment, the lesions tmned dark in color and within 
6 weeks the lesions had fallen off. This patient has had no 
recurrence of treated lesions in 2 years of follow-up , It is perhaps 
worthy of note that the disease has r emained under control 
even in areas not treated by PRT or by hyperthermia a nd 
radiation which was carried out subsequently in a few areas not 
previously treated , 
Malignant M elanoms 
To date 12 patients with malignant melanoma have been 
treated by PRT by various groups, ALI agree in fmding that the 
highly pigmented lesions a re only slightly or not at aU respon-
s ive to PRT, whereas the response of ligh tly pigmented lesions 
is similar to t hat of other types of lesions, Treatment, in general , 
has been described for basal cell carcinoma and Kaposi 's sar-
coma, However, we have recently found that a high dose rate 
of light delivered from the laser on only the individual lesions 
(to protect the skin) can resul t in eradication of the highJy 
pigmented lesions. 
Case III: A 67-yr-old male had more than 100 highly pig-
mented lesions of malignant mela noma covering the right arm 
a nd righ t chest wall. They ranged in size from 1-2 mm to 3 cm, 
He had been previously treated with a variety of systemic and 
topical drugs, none of which stopped the progression of t he 
disease, H e received 3,75 mg/kg Hpd and 4 days later, 6 of the 
la rger lesions were t reated with 70 to 140 Joules/cm2 of light 
from the laser delivered through the 200 J.LM fiber optic, The 
s maller lesions (> 100) received a total light dose of 60-120 
Joules delivered by impinging the fiber directly onto the lesion , 
At follow-up 6 weeks later , most of the smaller lesions were no 
longer evident, Four of these lesions showed a very small dark 
center which was assumed to be residual tumor and were 
retreated. Three of the larger lesions were eradicated and the 
others were retreated as previously, resulting in complete erad-
ication except for one which persisted and was excised. At 5 mo 
posttrea tment, the pa tient had 5 large nodules on t he chest wall 
which were excised but no other lesions were evident at that 
t ime. However, within the next several months, numerous new 
nod ules appeal'ed over a wider area than at the time of PRT, 
No further PRT was attempted, 
Metastatic Breast Carcinoma 
The majori ty of patients treated by PRT to date have had 
cutaneous or subcutaneous metastatic breast carcinoma, Many 
had metastatic disease elsewhere as well , Most patients had 
progressive or recurrent disease following several other treat-
ments such as sm gery, radiation therapy and multiple comses 
of chemotherapy. The 35 patients in this group had lesions 
ranging from a single large lesion (12 x 12 cm) to multiple small 
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lesions over areas ranging from 10 cm2 to the entire front and 
back chest wall. In this group, there were responses in 34 of 35 
patients, judged 4-6 weeks after t reatment (at least 50% reduc-
tion in size or extension of disease), Only 16 of t hese patients 
survived long enough for longer follow-up, In this group, 10 
showed recurrences in the t reated area, apparent 2 to 9 months 
fo ll owing treatment and 6 have not recurred up to 1 yr following 
treatment. In some cases, retreatment of recurrent lesions has 
resul ted in control. Patients with extensive, ulcerating disease 
frequently experience considerable pain due to treatment 
which, in some cases, necessitates termination of the treatment, 
It may be helpful , in t hese cases, to fractionate treatment. Such 
schedules ar e now being studied, In this group, the treatment 
is considered to be palliative since most go on to develop 
metastasis in other locations, 
Case IV: A 75-year-old woman had 40-50 palpable lesions on 
the chest wa ll over a n area of 200 cm 2, The disease had recurred 
following >5000 rads of radiot herapy and several courses of 
chemotherapy. She received 2,5 mg/kg Hpd and on the fourth 
day, a light dose of 60 J oules/ cmt delivered from the laser, At 
follow-up, 1 mo later, no nodules were found and no skin 
breakdown had occurred, At 4 mos, several 0,5 cm lesions 
appeared in the fi eld which were eradicated in the same manner 
as previously. This procedure has kept her disease under control 
for approximately 1 yr, to date, with little discomfort or skin 
necrosis in spite of the previous radition therapy treatment and 
mul t iple PRT treatments, 
DISCUSSION 
Photora diation therapy is still in a n early stage of develop-
ment for t reatment of malignant disease, However, it is clear 
that a wide variety of malignant lesions take up the photosen-
sit izing drug (Hpd), retain it and can be subsequently eradicated 
upon exposure to activating ligh t. The major problem, in many 
cases, is how to do this both effectively and selectively, T he 
t herapeutic ratio depends upon the relat ive drug levels in tumor 
and surrounding normal tissues exposed to similar doses of 
ligh t, Whil e many normal tissues clear the Hpd more rapidly 
tha n do the tumors, the kin, in fact, retains Hpd for up to 30 
days after injection , Therefore, it is necessary for patients 
receiving Hpd to avoid diJ'ect exposure to sunligh t for this 
period of time. In addi tion, studies of uptake and clearance of 
Hpd in mice, confirm that, although the skin levels a re lower 
by a fac tor of 2 or 3 than those of the tumor , Hpd is retained 
in the skin much longer than in tissues such as lung, stomach 
or muscle [8]. Consequently, when treating lesions involving 
the skin or below the sk in, response of the normal skin to the 
activating light is t he major factor limit ing the light dose, In 
spite of this, in most cases, especially for cutaneous lesions, an 
adequate ligh t dose can be delivered to the tumor without 
causing irreparable skin damage. However, this is not always 
the case, In some patients, a typical light dose of72 Joules/ cm2 
delivered fi'om the laser 3 or 5 days after 2,5 mg/ kg Hpd causes 
skin necrosis while such light doses are well tolera ted by others. 
Contri buting factors appear to be multiple drug doses given in 
less than a 2-month interva l (especially in obese patients), 
ulceration of the al'ea under treatment (Hpd is also taken up by 
t raumatized t issue), prior adJ'iamaycin plus ionizing radiation 
in the PRT field and inflammatory carcinoma. While, in these 
cases, adequate healing has always occurred, large eschars are 
quite painful to the patient and may require 1-2 mo to lift. Also, 
such an effect over a large a rea would be unacceptable, We 
fi'equently run test ar eas on small ar eas on the 3rd day a fter 
Hpd injection to avoid overtreating, However, since t he maxi-
mum reaction fTom these areas does not occur for 3 to 4 days 
after t reatment, it is fi'equently difficul t to interpret the effects 
on the day after the test dose is given when therapy is ini tiated, 
If the treatment is delayed until the reaction is known, sufficient 
Hpd may have c1 eru'ed fi'om the lesion for an adeq uate effect. 
Further, it is now clear that the test ru'eas shou ld be done in 
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t he area to be treated since reactions in remote areas can be 
very different. Complications of this sort, however, are rarely a 
problem when only small areas are treated (e.g. less than 10 
cm~ ) . 
Basal cell carcinoma lesions appear to be very responsive to 
PRT and since they can be treated before becoming large or 
wide spread, the treatment presents little discomfort to the 
patient. A good cosmetic effect has been seen in all cases, t hus 
making this a feasible treatment for basal cell carcinoma on the 
face. 
T reatment of metastasic pigmented malignant melanoma 
lesions is feasible using the laser system, although it is not 
unusual to find that the progression of new lesions occur almost 
as fast as the treated ones regress. 
While a few squamous cell lesions of the skin have been 
treated by PRT, no long-term follow-up has been obtained in 
these patients, a lthough t here are initial indications of response, 
However, squamous cell lesions in the bronchus are clearly 
responsive to PRT delivered through a bronchoscope and erad-
ication of such lesions has been reported [13]. 
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